托伐普坦治疗常染色体显性多囊肾病:所有问题都有答案吗?
本文针对托伐普坦延缓常染色体显性多囊肾病肾功能自然下降的作用提出质疑,指出已发表研究未明确其对肾脏总体积的影响、肝毒性后续剂量调整未报告、缺乏生活质量数据、成本效益临界、停药时机与无效标准未确立、高水量摄入能否模拟药物效应未知、用药后肾小球滤过率恶化原因不明。
要点
- 托伐普坦对肾脏总体积的影响尚不明确
- 肝毒性后剂量调整及生活质量数据缺失
- 停药时机与无效判定标准尚未确立
核心结论
- 托伐普坦虽可延缓ADPKD肾功能自然下降,但多项关键临床问题仍无答案。
主要发现
- 已发表研究未明确托伐普坦对肾脏总体积的影响。
- 肝毒性对后续托伐普坦剂量的影响未见报告。
- 缺乏托伐普坦对生活质量影响的数据。
- 托伐普坦的成本效益处于临界水平。
- 尚不清楚在肾功能衰竭的哪个阶段应停止托伐普坦治疗。
局限性
- 本文为观点性文章,未提供原始研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
According to recent literature, tolvaptan ameliorates the natural decline of renal function in autosomal dominant polycystic kidney disease. Tolvaptan is an orally available vasopressin V2 receptor antagonist. We describe herein the remaining questions and problems: it is unclear from the published work what influence tolvaptan has on total kidney volume. The consequences of hepatotoxicity for the subsequent dosing of tolvaptan have not been reported. A vasopressin V2 antagonist will cause polyuria and polydipsia and tolvaptan may influence quality of life (QOL), however, there are no QOL data. The cost-effectiveness of tolvaptan is borderline. It is unknown at which stage of renal failure tolvaptan therapy may have to be stopped. There are no established criteria to determine the ineffectiveness of tolvaptan. It is presently undecided whether a steady high water intake is able to imitate the renal effects of tolvaptan. Finally, the cause of worsening glomerular filtration rate after the start of tolvaptan is unknown.
引用
- Gross P, Schirutschke H, Paliege A, et al. Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers? Nephrol Dial Transplant. 2019. PMID: 30312449. doi:10.1093/ndt/gfy298
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。